ABL1 and acute lymphoblastic leukemia: Dasatinib, a novel ABL tyrosine kinase inhibitor, has been used for the treatment of relapsed and refractory Ph+-ALL and has been associated with significantly higher CR rate and lower toxicity than induction chemotherapy [7].